



# USCDI Task Force 2021 Call #2

Steven Lane, Co-Chair

Terry O'Malley, Co-Chair

February 9, 2021

---

Health Information Technology Advisory Committee

The Office of the National Coordinator for Health Information Technology



# Meeting Agenda

- Call to Order/Roll Call
- Review of Reformatted Task Force Charges
- Out of Scope Tasks – Level 1/Comment Elements
- Tasks 1a and 1b
- TF Schedule/Next Meeting
- Public Comment
- Adjourn



# Task Force Roster

Name	Organization
Steven Lane (Co-Chair)	Sutter Health
Terry O'Malley (Co-Chair)	Individual
Ricky Bloomfield	Apple
Hans Buitendijk	Cerner
Valerie Grey	New York eHealth Collaborative
Leslie Kelly Hall	Engaging Patient Strategy
Jim Jirjis	HCA Healthcare
Ken Kawamoto	University of Utah Health
Leslie Lenert	Medical University of South Carolina
Clement McDonald	National Library of Medicine

Name	Organization
Aaron Miri	University of Texas at Austin, Dell Medical School and UT Health Austin
Brett Oliver	Baptist Health
Mark Savage	University of California, San Francisco's Center for Digital Health Innovation
Michelle Schreiber	CMS
Sasha TerMaat	Epic
Andrew Truscott	Accenture
Sheryl Turney	Anthem, Inc.
Daniel Vreeman	RTI International
Denise Webb	Indiana Hemophilia and Thrombosis Center

# Task Force Charge

## Overarching charge:

Review and feedback on the Draft USCDI Version 2 content and process

## Specific charges:

### Due

**April 15, 2021**

**1 Evaluate Draft USCDI v2 and provide HITAC with recommendations for:**

**1a** - Data classes and elements from USCDI v1 including applicable standards version updates

**1b** - New data classes and elements from Draft USCDI v2 including applicable standards

**1c** - Level 2 data classes and elements not included in Draft USCDI v2

**2 Evaluate the USCDI expansion process and provide HITAC with recommendations for:**

**September 9, 2021**

**2a**- ONDEC submission system improvements

**2b** - Evaluation criteria and process used to assign levels to submitted data classes and elements

**2c** - Prioritization process used by ONC to select new data classes and elements for Draft USCDI v2

**3 Recommend ONC priorities for USCDI version 3 submission cycle**

**September 9, 2021**



# Draft USCDI v2 Public Comment Period Tasks

## Tasks Out of Scope for TF

### **Evaluate Level 1 and Comment Data Elements not included in Level 2**

- Process underway to engage between submitting stakeholders and ONC
- TF members may participate in this comment process individually

<b>Allergies and Intolerances</b> <ul style="list-style-type: none"> <li>• Substance (Medication)</li> <li>• Substance (Drug Class)</li> <li>• Reaction</li> </ul>	<b>Diagnostic Imaging</b> <ul style="list-style-type: none"> <li>• Diagnostic Imaging Order</li> <li>• Diagnostic Imaging Report</li> <li>• Diagnostic Imaging Narrative</li> </ul>	<b>Laboratory</b> <ul style="list-style-type: none"> <li>• Tests</li> <li>• Values/Results</li> <li>• Laboratory Report Narrative</li> <li>• Pathology Report Narrative</li> </ul>	<b>Problems</b> <ul style="list-style-type: none"> <li>• Problems</li> <li>• Date of Diagnosis</li> <li>• Date of Resolution</li> </ul>	<b>Vital Signs</b> <ul style="list-style-type: none"> <li>• Diastolic Blood Pressure</li> <li>• Systolic Blood Pressure</li> <li>• Body Height</li> <li>• Body Weight</li> <li>• Heart Rate</li> <li>• Respiratory Rate</li> <li>• Body Temperature</li> <li>• Pulse Oximetry</li> <li>• Inhaled Oxygen Concentration</li> <li>• BMI Percentile (2-20 Years)</li> <li>• Weight-for-length Percentile (Birth-36 Months)</li> <li>• Occipital-frontal Head Circumference Percentile (Birth-36 Months)</li> </ul>
<b>Assessment and Plan of Treatment</b> <ul style="list-style-type: none"> <li>• Assessment and Plan of Treatment</li> </ul>	<b>Encounter Information</b> <ul style="list-style-type: none"> <li>• Encounter Type</li> <li>• Encounter Diagnosis</li> <li>• Encounter Time</li> </ul>	<b>Medications</b> <ul style="list-style-type: none"> <li>• Medications</li> </ul>	<b>Procedures</b> <ul style="list-style-type: none"> <li>• Procedures</li> </ul>	
<b>Care Team Members</b> <ul style="list-style-type: none"> <li>• Care Team Members</li> <li>• Provider Name</li> <li>• Provider Identifier</li> </ul>	<b>Goals</b> <ul style="list-style-type: none"> <li>• Patient Goals</li> </ul>	<b>Patient Demographics</b> <ul style="list-style-type: none"> <li>• First Name</li> <li>• Last Name</li> <li>• Previous Name</li> <li>• Middle Name (incl. middle initial)</li> <li>• Suffix</li> <li>• Birth Sex</li> <li>• Date of Birth</li> <li>• Race</li> <li>• Ethnicity</li> <li>• Preferred Language</li> <li>• Current Address</li> <li>• Previous Address</li> <li>• Phone Number</li> <li>• Phone Number Type</li> <li>• Email Address</li> </ul>	<b>Provenance</b> <ul style="list-style-type: none"> <li>• Author Time Stamp</li> <li>• Author Organization</li> </ul>	
<b>Clinical Notes</b> <ul style="list-style-type: none"> <li>• Consultation Note</li> <li>• Discharge Summary Note</li> <li>• History &amp; Physical</li> <li>• Procedure Note</li> <li>• Progress Note</li> </ul>	<b>Health Concerns</b> <ul style="list-style-type: none"> <li>• Health Concerns</li> </ul>		<b>Smoking Status</b> <ul style="list-style-type: none"> <li>• Smoking Status</li> </ul>	
<b>Clinical Notes</b> <ul style="list-style-type: none"> <li>• Consultation Note</li> <li>• Discharge Summary Note</li> <li>• History &amp; Physical</li> <li>• Procedure Note</li> <li>• Progress Note</li> </ul>	<b>Immunizations</b> <ul style="list-style-type: none"> <li>• Immunizations</li> </ul>		<b>Unique Device Identifier(s) for a Patient's Implantable Device(s)</b> <ul style="list-style-type: none"> <li>• Unique Device Identifier(s) for a Patient's Implantable Device(s)</li> </ul>	

Key  New Data Class or Element  
 Data Element reclassified

# Task Force Charge 1a

- |   | <b><u>Due</u></b>        |
|---|--------------------------|
| <b>1 Evaluate Draft USCDI v2 and provide HITAC with recommendations for:</b>                              | <b>April 15, 2021</b>    |
| <b>1a - Data classes and elements from USCDI v1 including applicable standards version updates</b>        |                          |
| <b>1b - New data classes and elements from Draft USCDI v2 including applicable standards</b>              |                          |
| <b>1c - Level 2 data classes and elements not included in Draft USCDI v2</b>                              |                          |
| <b>2 Evaluate the USCDI expansion process and provide HITAC with recommendations for:</b>                 | <b>September 9, 2021</b> |
| <b>2a- ONDEC submission system improvements</b>   |                          |
| <b>2b - Evaluation criteria and process used to assign levels to submitted data classes and elements</b>  |                          |
| <b>2c - Prioritization process used by ONC to select new data classes and elements for Draft USCDI v2</b> |                          |
| <b>3 Recommend ONC priorities for USCDI version 3 submission cycle</b>                                    | <b>September 9, 2021</b> |

# Draft USCDI version 2

## Updated Applicable Standards Versions

- USCDI v1

- RxNorm - January 6, 2020
- SNOMED CT - September 2019
- LOINC 2.67
- ICD-10-PCS 2020
- CVX - January 31, 2020
- Vaccine NDC Linker - January 31, 2020
- CPT 2020



Updated

- Draft USCDI v2

- RxNorm - January 4, 2021
- SNOMED CT - September 2020
- LOINC 2.69
- ICD-10-PCS 2021
- CVX - November 16, 2020
- Vaccine NDC Linker - November 13, 2020
- CPT 2021



# Draft USCDI version 2 Reclassified Clinical Note Data Elements

- Clinical Notes
    - Consultation Note
    - Discharge Summary Note
    - History & Physical
    - Procedure Note
    - Progress Note
    - Diagnostic Imaging Narrative
    - Laboratory Report Narrative
    - Pathology Report Narrative
- Reclassified
- Diagnostic Imaging
    - Diagnostic Imaging Narrative
  - Laboratory
    - Laboratory Report Narrative
    - Pathology Report Narrative

## Task 1a –Data Elements and Classes from USCDI v1

- Comments
- Additions
- Clarifications/Modifications

<b>Allergies and Intolerances</b> <ul style="list-style-type: none"> <li>• Substance (Medication)</li> <li>• Substance (Drug Class)</li> <li>• Reaction</li> </ul>	<b>Diagnostic Imaging</b> <ul style="list-style-type: none"> <li>• Diagnostic Imaging Order</li> <li>• Diagnostic Imaging Report</li> <li>• Diagnostic Imaging Narrative</li> </ul>	<b>Laboratory</b> <ul style="list-style-type: none"> <li>• Tests</li> <li>• Values/Results</li> <li>• Laboratory Report Narrative</li> <li>• Pathology Report Narrative</li> </ul>	<b>Problems</b> <ul style="list-style-type: none"> <li>• Problems</li> <li>• Date of Diagnosis</li> <li>• Date of Resolution</li> </ul>	<b>Vital Signs</b> <ul style="list-style-type: none"> <li>• Diastolic Blood Pressure</li> <li>• Systolic Blood Pressure</li> <li>• Body Height</li> <li>• Body Weight</li> <li>• Heart Rate</li> <li>• Respiratory Rate</li> <li>• Body Temperature</li> <li>• Pulse Oximetry</li> <li>• Inhaled Oxygen Concentration</li> <li>• BMI Percentile (2-20 Years)</li> <li>• Weight-for-length Percentile (Birth-36 Months)</li> <li>• Occipital-frontal Head Circumference Percentile (Birth-36 Months)</li> </ul>
<b>Assessment and Plan of Treatment</b> <ul style="list-style-type: none"> <li>• Assessment and Plan of Treatment</li> </ul>	<b>Encounter Information</b> <ul style="list-style-type: none"> <li>• Encounter Type</li> <li>• Encounter Diagnosis</li> <li>• Encounter Time</li> </ul>	<b>Medications</b> <ul style="list-style-type: none"> <li>• Medications</li> </ul>	<b>Procedures</b> <ul style="list-style-type: none"> <li>• Procedures</li> </ul>	
<b>Care Team Members</b> <ul style="list-style-type: none"> <li>• Care Team Members</li> <li>• Provider Name</li> <li>• Provider Identifier</li> </ul>	<b>Goals</b> <ul style="list-style-type: none"> <li>• Patient Goals</li> </ul>	<b>Patient Demographics</b> <ul style="list-style-type: none"> <li>• First Name</li> <li>• Last Name</li> <li>• Previous Name</li> <li>• Middle Name (incl. middle initial)</li> <li>• Suffix</li> <li>• Birth Sex</li> <li>• Date of Birth</li> <li>• Race</li> <li>• Ethnicity</li> <li>• Preferred Language</li> <li>• Current Address</li> <li>• Previous Address</li> <li>• Phone Number</li> <li>• Phone Number Type</li> <li>• Email Address</li> </ul>	<b>Provenance</b> <ul style="list-style-type: none"> <li>• Author Time Stamp</li> <li>• Author Organization</li> </ul>	
<b>Clinical Notes</b> <ul style="list-style-type: none"> <li>• Consultation Note</li> <li>• Discharge Summary Note</li> <li>• History &amp; Physical</li> <li>• Procedure Note</li> <li>• Progress Note</li> </ul>	<b>Health Concerns</b> <ul style="list-style-type: none"> <li>• Health Concerns</li> </ul>		<b>Smoking Status</b> <ul style="list-style-type: none"> <li>• Smoking Status</li> </ul>	
	<b>Immunizations</b> <ul style="list-style-type: none"> <li>• Immunizations</li> </ul>		<b>Unique Device Identifier(s) for a Patient's Implantable Device(s)</b> <ul style="list-style-type: none"> <li>• Unique Device Identifier(s) for a Patient's Implantable Device(s)</li> </ul>	

Key  New Data Class or Element  
 Data Element reclassified

# Task Force Charge

## Due

**April 15, 2021**

**1 Evaluate Draft USCDI v2 and provide HITAC with recommendations for:**

**1a** - Data classes and elements from USCDI v1 including applicable standards version updates

**1b** - New data classes and elements from Draft USCDI v2 including applicable standards

**1c** - Level 2 data classes and elements not included in Draft USCDI v2

**2 Evaluate the USCDI expansion process and provide HITAC with recommendations for:**

**September 9, 2021**

**2a**- ONDEC submission system improvements

**2b** - Evaluation criteria and process used to assign levels to submitted data classes and elements

**2c** - Prioritization process used by ONC to select new data classes and elements for Draft USCDI v2

**3 Recommend ONC priorities for USCDI version 3 submission cycle**

**September 9, 2021**

# Draft USCDI version 2

## New Data Classes and Elements

- Care Team Members
  - Provider Name
  - Provider Identifier
- Diagnostic Imaging
  - Diagnostic Imaging Order
  - Diagnostic Imaging Report
- Encounter Information
  - Encounter Type
  - Encounter Diagnosis
  - Encounter Time
- Problems
  - Date of Diagnosis
  - Date of Resolution

# Task 1b – New Data Elements and Classes


- Comments
- Additions
- Clarifications/Modifications

# USCDI Version Update Process

2020

2021

2022



## Next TF Meetings

- February 16, 2021      10:30 a.m. - 12:00 p.m. ET
- February 23, 2021      10:30 a.m. - 12:00 p.m. ET
- March 2, 2021          10:30 a.m. - 12:00 p.m. ET
- March 9, 2021         10:30 a.m. - 12:00 p.m. ET





# Public Comment

To make a comment please call:  
**Dial: 1-877-407-7192**

*(Once connected, press “\*1” to speak)*

**All public comments will be limited to three minutes.**

You may enter a comment in the  
**“Public Comment”** field below this presentation.

Or, email your public comment to [onc-hitac@accelsolutionsllc.com](mailto:onc-hitac@accelsolutionsllc.com).

*Written comments will not be read at this time,  
but they will be delivered to members of the Task Force and made part of the Public Record.*



**Questions?**



**Meeting  
Adjourned**